Hydroxychloroquine retinopathy screening

British Journal of Ophthalmology

Volumn 92, Issue 12, 2008, Pages 1653-1655

  Semmer, A E ^a   Lee, M S ^a,c   Harrison, A R ^a   Olsen, T W ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYCHLOROQUINE;

ADULT; AGED; ARTICLE; COST BENEFIT ANALYSIS; DEMOGRAPHY; EVIDENCE BASED MEDICINE; FOLLOW UP; HEALTH SURVEY; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; OPHTHALMOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETINOPATHY; RISK FACTOR; SCREENING;

ADULT; AGED; ANTIRHEUMATIC AGENTS; CLINICAL COMPETENCE; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE SURVEYS; HUMANS; HYDROXYCHLOROQUINE; MALE; MASS SCREENING; MIDDLE AGED; OPHTHALMOLOGY; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; RETINAL DISEASES;

EID: 57149116988     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2008.144402     Document Type: Article

References (15)

1. Hobbs H, Sorsby A, Freedman A. Retinopathy following chloroquine therapy. Lancet 1959;2:478-80.
2. Levy GC, Munz SJ, Paschal J, et al. Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice. Arthritis Rheum 1997;40:1482-6.
3. Finbloom DS, Silver K, Newsome DA, et al. Comparison of hydroxychloroquine and chloroquine use and the development of retinal toxicity. J Rheumatol 1985;12:692-4.
4. Bernstein HN. Ocular safety of hydroxychloroquine. Ann Ophthalmol 1991;23:292-6.
5. Yam JC, Kwok AK. Ocular toxicity of hydroxychloroquine. Hong Kong Med J 2006;12:294-304.
6. Easterbrook M. Screening for antimalarial toxicity. Can J Ophthalmol 1993;28:51-2.
7. Ruiz RS, Saatci OA. Chloroquine and hydroxychloroquine retinopathy: how to follow affected patients. Ann Ophthalmol 1991;23:290-1.
8. Marmor MF, Carr RE, Easterbrook M, et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. Ophthalmology 2002;109:1377- 82.
9. American Academy of Ophthalmology. Comprehensive adult medical eye evaluation, preferred practice pattern. San Francisco: American Academy of Ophthalmology, 2005. http://www.aao.org/ppp (accessed 5 Oct 2008).
10. Grierson DJ. Hydroxychloroquine and visual screening in a rheumatology outpatient clinic. Ann Rheum Dis 1997;56:188-90.
11. Elder M, Rahman AM, McLay J. Early paracentral visual field loss in patients taking hydroxychloroquine. Arch Ophthalmol 2006;124:1729-33.
12. Lai TY, Chan WM, Li H, et al. Multifocal electroretinographic changes in patients receiving hydroxychloroquine therapy. Am J Ophthalmol 2005;140:794-807.
13. Lyons JS, Severns ML. Detection of early hydroxychloroquine retinal toxicity enhanced by ring ratio analysis of multifocal electroretinography. Am J Ophthalmol 2007;143:801-9.
14. Marmor MF. The dilemma of hydroxychloroquine screening: new information from the multifocal ERG. Am J Ophthalmol 2005;140:894- 5.
15. Flach AJ. Improving the risk-benefit relationship and informed consent for patients treated with hydroxychloroquine. Trans Am Ophthalmol Soc 2007;105:191-7.